Search

Yingjie C Lu

from Lexington, MA
Age ~49
Get Report
Also known as:
Ying Jie Lu, Ying J Lu, Lu Yingjie, Yngjie Lu, Ying-Jie Lu
Connected to:
Abigail I Lu, 32Aiping Lu, 54Allen C Lu, 46Anjian Lu, 84Anna G Lu, 67Anne B Lu, 71Arnold W Lu, 49Ava Lu, 36Ay K Lu, 54Barbara T Lu, 74

Yingjie Lu Phones & Addresses

  • Lexington, MA
  • 38 Gerry Rd, Chestnut Hill, MA 02467
  • 706 Huntington Ave #401, Boston, MA 02115
  • West Roxbury, MA
  • 105 Harbor Village Dr, Memphis, TN 38103
  • 99 Main St, Memphis, TN 38103

Resumes

Resumes

Yingjie Lu Photo 1

Assistant Professor

View page
Location:
New York, NY
Industry:
Hospital & Health Care
Work:
Boston Children's Hospital
Assistant Professor
Boston Children's Hospital Jul 2009 - Oct 2012
Instructor
Boston Children's Hospital Mar 2007 - Jul 2009
Research Fellow
St. Jude Children's Research Hospital Sep 2002 - Feb 2007
Research Associate
Education:
Tsinghua University 1999 - 2002
Tsinghua University 1997 - 1999
Masters, Biophysics Tsinghua University 1992 - 1997
Bachelors, Biotechnology
Skills:
Cell
Biochemistry
Molecular Biology
Animal Models
Antibodies
High Throughput Screening
Interests:
Soccer
New Technology
Yingjie Lu Photo 2

Yingjie Lu

View page

Publications

Us Patents

Selectively Disrupted Whole-Cell Vaccine

View page
US Patent:
20120251577, Oct 4, 2012
Filed:
Oct 12, 2010
Appl. No.:
13/500925
Inventors:
Richard Malley - Beverly MA, US
Porter Anderson - Key Largo FL, US
Yingjie Lu - West Roxbury MA, US
George A. Robertson - Fairfax Station VA, US
Mark Alderson - Bainbridge Island WA, US
Jean-Francois Lucien Maisonneuve - Federal Way WA, US
Andrea Maria Tate - Issaquah WA, US
Waldely de Oliveira Dias - Sao Paulo, BR
Viviane Maimoni Gonçalves - Sao Paulo, BR
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
FUNDACAO BUTANTAN - Sao Paulo
PATH VACCINE SOLUTIONS - Seattle WA
International Classification:
A61K 39/02
A61P 37/04
A61P 31/04
A61K 39/09
US Classification:
4242441, 4242341
Abstract:
The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.

Novel Immunogens And Methods For Discovery And Screening Thereof

View page
US Patent:
20130039947, Feb 14, 2013
Filed:
Mar 11, 2011
Appl. No.:
13/634357
Inventors:
Richard Malley - Beverly MA, US
Yingjie Lu - West Roxbury MA, US
Kristin L. Moffitt - Woburn MA, US
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 39/09
A61P 31/04
G01N 33/53
A61K 39/02
C07K 14/315
US Classification:
4242441, 4242341, 530350, 435 792
Abstract:
The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

Novel Immunogens And Methods For Discovery And Screening Thereof

View page
US Patent:
20110159040, Jun 30, 2011
Filed:
Dec 30, 2010
Appl. No.:
12/981706
Inventors:
Richard Malley - Beverly MA, US
Yingjie Lu - Chestnut Hill MA, US
Kristin L. Moffitt - Woburn MA, US
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 39/09
C07K 1/14
C07H 1/06
C07C 51/42
G01N 33/68
C12Q 1/02
A61P 37/04
A61P 31/04
US Classification:
4242441, 530412, 536 254, 554206, 536127, 436501, 435 29
Abstract:
An aspect of the present invention provides for methods for identifying novel immunogens that when administered as vaccines elicit a cellular or humoral immunogenic response. In a particular embodiment, a method identified pneumococcal T-cell immunogens that elicit systemic IL-17A responses, and reduce or protect against pneumococcal colonization.

Novel Immunogens And Methods For Discovery And Screening Thereof

View page
US Patent:
20220378895, Dec 1, 2022
Filed:
Jan 7, 2022
Appl. No.:
17/571079
Inventors:
- Boston MA, US
Yingjie Lu - West Roxbury MA, US
Kristin L. Moffitt - Woburn MA, US
Assignee:
Children's Medical Center Corporation - Boston MA
International Classification:
A61K 39/09
A61P 37/04
Abstract:
The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

Multiple Antigen Presenting System (Maps)-Based Staphylococcus Aureus Vaccine, Immunogenic Composition, And Uses Thereof

View page
US Patent:
20220362367, Nov 17, 2022
Filed:
Mar 7, 2022
Appl. No.:
17/688780
Inventors:
- Boston MA, US
Fan ZHANG - Chestnut Hill MA, US
Yingjie LU - Chestnut Hill MA, US
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 39/085
Abstract:
The present embodiments provide for an (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from , or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.

Pneumococcal Fusion Protein Vaccines

View page
US Patent:
20230089151, Mar 23, 2023
Filed:
Sep 16, 2022
Appl. No.:
17/932685
Inventors:
- Boston MA, US
Yingjie LU - West Roxbury MA, US
Fan ZHANG - West Roxbury MA, US
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
C07K 14/47
C07K 14/315
Abstract:
Technologies for the prevention and/or treatment of pneumococcal infections.

Multivalent Pneumococcal Vaccines

View page
US Patent:
20230091255, Mar 23, 2023
Filed:
Sep 9, 2022
Appl. No.:
17/942089
Inventors:
- Cambridge MA, US
Teresa J. Broering - Brookline MA, US
Heidi Burke - Wakefield MA, US
Yingjie Lu - West Roxbury MA, US
Richard Malley - Beverly MA, US
Janet E. McCombs - New Orleans LA, US
Velupillai Puvanesarajah - Chapel Hill NC, US
Shite Sebastian - Shrewsbury MA, US
Onkar Sharma - Chestnut Hill MA, US
Taylor C. Stevenson - Cambridge MA, US
Gang Yao - Belmont MA, US
Fan Zhang - West Roxbury MA, US
International Classification:
A61K 39/09
Abstract:
Technologies for the prevention and/or treatment of pneumococcal infections.

Protein Antigens That Provide Protection Against Pneumococcal Colonization And/Or Disease

View page
US Patent:
20230081705, Mar 16, 2023
Filed:
Jun 7, 2022
Appl. No.:
17/834865
Inventors:
- Boston MA, US
Yingjie LU - West Roxbury MA, US
Fan ZHANG - West Roxbury MA, US
Assignee:
CHILDREN'S MEDICAL CENTER CORPORATION - Boston MA
International Classification:
A61K 39/09
C07K 14/315
Abstract:
The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individualand/or therapeutically to induce a thereapeutic immune response to an infected individual.
Control profile
Yingjie C Lu from Lexington, MA, age ~49 Get Report